Sanofi

Merck & Co’s PD-1 inhibitor for multiple cancer indications Keytruda (pembrolizumab) comfortably retained its number one spot as the drug generating the highest global revenues in the first quarte

Huntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti

The US Food and Drug Administration’s July advisory committee schedule includes a curious mix of vaccine safety reviews and the potentially triumphant return of a pulled multiple myeloma drug, in addi

Sanofi’s plans for rilzabrutinib continue apace with positive mid-stage data in IgG4-related disease ahead of a potential US approval in the summer for the potential ‘pipeline-in-a-product’ in immune